Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02686268|
Recruitment Status : Completed
First Posted : February 19, 2016
Last Update Posted : October 4, 2018
|Condition or disease|
|C9ORF72 Amyotrophic Lateral Sclerosis (ALS)|
Individuals diagnosed with ALS, who are confirmed to carry the Chromosome 9 Open Reading Frame 72 (C9ORF72) gene mutation by CLIA-certified lab results, are eligible for enrollment. Researchers want to understand the natural history of C9ORF72 related ALS in terms of measures of rate of progression as well as understanding how the size of the hexanucleotide repeat expansion influences disease parameters. The investigators hope that the intense study of patients with the C9ORF72 mutation will ultimately help us develop treatments for this common form of ALS.
- Enroll a total of 120 C9ORF72 ALS participants with known mutation at the time of enrollment.
- Determine the C9ORF72 hexanucleotide repeat expansion size in all subjects
- Define ALS disease course
- Determine to what degree the disease course correlates with expansion size
- Collect biomarker samples (blood, DNA and CSF)
- Adults over age 18 with known C9ORF72 ALS status
Participants will have up to 9 in-person visits (this includes two Optional visits for lumbar puncture procedures) and 5 telephone interviews over 3 years. Each in-person visit may be tied to a regular clinic visit if subject is local (except for the optional lumbar puncture visits) or if the subject is from out of town one initial visit can be set up with all other visits performed via a telephone call and medical records review.
At each in town visit, subjects will undergo a blood draw (optional lumbar puncture) and two questionnaires (ALS Functional Rating Scale - revised ALSFRS-R) which measures motor function and the ALS-Cognitive Behavioral Screen (ALS-CBS) which will detect signs of Frontal Temporal Dementia and a breathing test to determine Slow Vital Capacity (SVC) measurements.
For out of town subjects - blood draws can be scheduled locally and sent to the study site for analysis. The ALSFRS-R can be performed over the phone along with other study related questions.
The C9ORF72 mutation is called a "dominant" mutation, which means that their children have a 50% chance of inheriting the gene. Most people who inherit the C9ORF72 mutation will develop either ALS or the related disease called fronto-temporal dementia. However, it may be possible for someone to test positive for the C9ORF72 gene mutation and never develop symptoms. Furthermore, in addition to C9ORF72, there are many other gene mutations that can cause ALS. This study will not test these other genes, and therefore a negative test result for the C9ORF72 mutation will not exclude the possibility that you have a heritable form of ALS.
In order to understand the natural history of C9ORF72 related ALS in terms of measures of rate of progression, the investigators need to understand how the size of the hexanucleotide repeat expansion influences disease parameters. A C9ORF72-focused clinical trial defining an accurate historical control population, will be critical since there may not be enough subjects for a placebo controlled trial. To be ready for upcoming therapeutic trials, the investigators need to start the detailed characterization of the C9ORF72 patients immediately.
|Study Type :||Observational|
|Actual Enrollment :||128 participants|
|Official Title:||Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS|
|Study Start Date :||February 2015|
|Actual Primary Completion Date :||December 31, 2017|
|Actual Study Completion Date :||October 2, 2018|
Individuals diagnosed with known positive C9ORF72 ALS
Individuals diagnosed with known positive C9ORF72 ALS
- Collection of clinical data and biomarker samples [ Time Frame: December 2017 ]The primary outcome measures will be the collection of clinical data (ALSFRS, ALS-CBS and SVC) to determine rates of disease progression and collection of biomarkers samples (blood, CSF) to be correlated with the clinical measures.
- Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials [ Time Frame: December 2017 ]The secondary outcome measures include determination of the C9ORF72 hexanucleotide repeat expansion size and correlating this with the outcome measures of disease progression collected (ALSFRS-R/month, decrease in SVC/month and ALS Cognitive Screen) and determination of C9ORF72 ALS patients that may be available for a clinical trial.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02686268
|United States, California|
|Cedars Sinai Medical Center|
|Los Angeles, California, United States, 90048|
|United States, Maryland|
|Baltimore, Maryland, United States, 21287|
|United States, Massachusetts|
|University of Massachusetts|
|Amherst, Massachusetts, United States, 01003|
|Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|United States, Missouri|
|Washington University in St. Louis|
|Saint Louis, Missouri, United States, 63110|
|United States, New York|
|Columbia University Medical Center|
|New York, New York, United States, 10027|
|United States, Virginia|
|Sentara Health Care / Sentara Neurology Specialists|
|Virginia Beach, Virginia, United States, 23454|
|Principal Investigator:||Timothy M Miller, MD, PhD||Washington University School of Medicine|